154 related articles for article (PubMed ID: 8712747)
1. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo).
Buggia I; Zecca M; Alessandrino EP; Locatelli F; Rosti G; Bosi A; Pession A; Rotoli B; Majolino I; Dallorso A; Regazzi MB
Anticancer Res; 1996; 16(4A):2083-8. PubMed ID: 8712747
[TBL] [Abstract][Full Text] [Related]
2. BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study.
Lemoli RM; D'Addio A; Marotta G; Pezzullo L; Zuffa E; Montanari M; De Vivo A; Bonini A; Galieni P; Carella AM; Guidi S; Michieli M; Olivieri A; Bosi A
Bone Marrow Transplant; 2010 Apr; 45(4):640-6. PubMed ID: 19802019
[TBL] [Abstract][Full Text] [Related]
3. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
[TBL] [Abstract][Full Text] [Related]
4. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.
Shaw PJ; Nath C; Berry A; Earl JW
Bone Marrow Transplant; 2004 Aug; 34(3):197-205. PubMed ID: 15195074
[TBL] [Abstract][Full Text] [Related]
5. Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation.
Kim AH; Tse JC; Ikeda A; Moore TB
Pediatr Transplant; 2009 Dec; 13(8):971-6. PubMed ID: 19032412
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation.
Annaloro C; Oriana A; Tagliaferri E; Bertolli V; Della Volpe A; Soligo D; Ibatici A; Pozzoli E; Lambertenghi Deliliers GL
Haematologica; 1995; 80(6):512-7. PubMed ID: 8647515
[TBL] [Abstract][Full Text] [Related]
7. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study.
Bertholle-Bonnet V; Bleyzac N; Galambrun C; Mialou V; Bertrand Y; Souillet G; Aulagner G
Ther Drug Monit; 2007 Apr; 29(2):177-84. PubMed ID: 17417071
[TBL] [Abstract][Full Text] [Related]
8. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
9. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease.
Bolinger AM; Zangwill AB; Slattery JT; Glidden D; DeSantes K; Heyn L; Risler LJ; Bostrom B; Cowan MJ
Bone Marrow Transplant; 2000 May; 25(9):925-30. PubMed ID: 10800058
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
[TBL] [Abstract][Full Text] [Related]
12. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients.
Ljungman P; Hassan M; Békássy AN; Ringdén O; Oberg G
Bone Marrow Transplant; 1997 Dec; 20(11):909-13. PubMed ID: 9422468
[TBL] [Abstract][Full Text] [Related]
13. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.
Nilsson C; Aschan J; Hentschke P; Ringdén O; Ljungman P; Hassan M
Bone Marrow Transplant; 2003 Mar; 31(6):429-35. PubMed ID: 12665836
[TBL] [Abstract][Full Text] [Related]
14. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
[TBL] [Abstract][Full Text] [Related]
15. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders.
Foot AB; Veys PA; Gibson BE
Bone Marrow Transplant; 1999 Nov; 24(10):1089-93. PubMed ID: 10578159
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
[TBL] [Abstract][Full Text] [Related]
17. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
Nguyen L; Leger F; Lennon S; Puozzo C
Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
[TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
20. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO).
Iacopino P; Pucci G; Arcese W; Bosi A; Falda M; Locatelli F; Marenco P; Miniero R; Morabito F; Rossetti F; Sica S; Uderzo C; Bacigalupo A
Bone Marrow Transplant; 1999 Jul; 24(1):47-51. PubMed ID: 10435734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]